Profile: Incyte Corp (INCY.O)
20 May 2019
Incyte Corporation, incorporated on April 8, 1991, is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics. The Company's portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). The Company has initiated REACH1, a pivotal Phase II trial in steroid-refractory acute graft-versus-host-disease (GVHD) and the first in a registration program for ruxolitinib in GVHD. A proof-of-concept trial of itacitinib, a selective janus associated kinases 1 (JAK1) inhibitor, is ongoing for the treatment of patients with acute GVHD.
The Company has a portfolio of selective JAK1 inhibitors, including itacitinib and INCB52793. INCB52793 is in a Phase I/II trial in patients with advanced malignancies. INCB54828 is an inhibitor of the Fibroblast Growth Factor Receptor (FGFR) isoforms 1, 2 and 3. The Company is studying its bromodomain (BRD) inhibitors, INCB54329 and INCB57643, in open-label dose-escalation trials in patients with advanced malignancies. INCB53914 is a pan-PIM kinase inhibitor. INCB59872 is a lysine (K)-specific demethylase 1A (LSD1) inhibitor. INCB62079 is a selective, irreversible inhibitor of FGFR4. Epacadostat is a potent and selective inhibitor of the enzyme indoleamine 2, 3-dioxygenase-1 (IDO1). INCSHR1210 is an anti-programmed cell death protein 1 (PD-1) monoclonal antibody. It has two co-stimulatory antibodies in clinical development. INCAGN1876 is an anti-glucocorticoid-induced tumor necrosis factor (TNF) Receptor (GITR) agonist antibody and INCAGN1949 is an anti-OX40 agonist antibody.
As of December 31, 2016, the Company offered two platform studies to investigate the effects of PD-1, JAK1, IDO1 and Phosphatidylinositol-3-kinase delta (PI3Kd) inhibition on the tumor microenvironment. The PD-1 platform study is investigating the effects of adding either itacitinib (JAK1) or INCB50465 (PI3Kd) to pembrolizumab (PD-1). The JAK1 platform study is investigating all-oral doublets combining either INCB50465 (PI3Kd) or epacadostat (IDO1) with itacitinib (JAK1). It has initiated a Phase II trial of ruxolitinib cream for the topical treatment of alopecia areata. It has also initiated a Phase II trial of ruxolitinib cream for the topical treatment of atopic dermatitis. Its partnered programs include Baricitinib, which is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, systemic lupus and erythematosus, and Capmatinib, which is indicated for the treatment of non-small cell lung (NSCLC) and liver cancer.
The Company's product, JAKAFI (ruxolitinib), is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. The Company has initiated a research and development program to explore the inhibition of enzymes called JAK. It has discovered multiple potent, selective and orally bioavailable JAK inhibitors that are selective for JAK1 or JAK1 and JAK2. JAKAFI is the advanced compound in its JAK program. It is an oral JAK1 and JAK2 inhibitor. The Food and Drug Administration (FDA) has granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. JAKAFI is distributed primarily through a network of specialty pharmacy providers and wholesalers.
ICLUSIG is a kinase inhibitor. The primary target for ICLUSIG is B Cell Receptor-ABL (BCR-ABL), an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ICLUSIG is indicated for the treatment of adult patients with chronic phase, accelerated phase or blast phase CML, resistant to dasatinib or nilotinib; intolerant to dasatinib or nilotinib; for whom subsequent treatment with imatinib is not clinically appropriate; or having the T315I mutation; or the treatment of adult patients with Ph+ ALL resistant to dasatinib; intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or having the T315I mutation.
1801 Augustine Cut off
WILMINGTON DE 19803-4404